LONDON (Reuters) – Britain’s medicines regulator said on Wednesday that final late-stage trial results from Pfizer and BioNTech’s COVID-19 vaccine candidate were very encouraging, adding it would need to see the full data before making an assessment of the shot.
Pfizer Inc. will seek emergency U.S. approval for its COVID-19 vaccine within days after final trial resultsshowed its shot had a 95% success rate and no serious side effects, the drugmaker said on Wednesday.
“The results reported by Pfizer today are very encouraging and add to their announcement last week,”
June Raine, Chief Executive of Medicines and Healthcare products Regulatory Agency (MHRA), said in a statement, which did not give a precise timeframe for UK regulatory approval.
Join The European Business Briefing
New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.
Subscribe“We look forward to receiving the full results of the trials as soon as possible, after which we will
rigorously assess the evidence of safety and effectiveness of the vaccine.”
